Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience

AIDS Patient Care and STDs

Volumn 25, Issue 1, 2011, Pages 29-36

  Larder, Brendan A ^a   Revell, Andrew ^a   Mican, Joann M ^b   Agan, Brian K ^c   Harris, Marianne ^d   Torti, Carlo ^e   Izzo, Ilaria ^e   Metcalf, Julia A ^b   Rivera Goba, Migdalia ^f   Marconi, Vincent C ^c   Wang, Dechao ^a   Coe, Daniel ^a   Gazzard, Brian ^g   Montaner, Julio ^d   Lane, H Clifford ^b  

^a The HIV Resistance Response Database Initiative (RDI)   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e UNIVERSITY OF BRESCIA   (Italy)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DECISION SUPPORT SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNET; PATIENT SATISFACTION; PHYSICIAN; RESPONSE DATABASE INITIATIVE; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COMPUTER SIMULATION; DECISION MAKING; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 78651264714     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0254     Document Type: Article

References (21)

1. Thompson MA, Aberg JA, Cahn C, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society\USA Panel. JAMA 2010;304: 321-333.
2. Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1,2009;1-161. www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last ac-cessed July 30, 2010).
3. Hirsch MS, Günthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recom-mendations of an International AIDS Society\USA panel. Clin Infect Dis 2008;47:266-285.
4. Sturmer M, Doerr HW, Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 geno-typing: Confirmatory information or additional confusion? Curr Drug Targets Infect Disord 2003;3:373-382.
5. Schapiro JM, De Luca A, Harrigan R, et al. Resistance assay interpretation systems vary widely in method and approach. Antivir Ther 2001;6(Suppl 1):131.
6. Shafer RW, Gonzales MJ, Brun-Vezinet F. Online compari-son of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antivir Ther 2001;6:101.
7. Torti C, Quiros-Roldan E, Keulen W, et al. For the Gen-Pherex Group of the MaSTeR Cohort. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: Concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis 2003;188:194-201
8. Sturmer M, Doerr HW, Staszewski S, Preiser W. Compar-ison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003;8:239-244.
9. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;15:1934-1943
10. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
11. Frentz D, Boucher CAB, AsselM, et al. Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PLoS One 2010;5:e11505.
12. Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Corral A, Soriano V. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. J Virol Methods 2004;121:115-118.
13. Larder BA, Revell A, Wang D, Harrigan R, Montaner J, Wegner S. Neural networks are more accurate predictors of virological response to antiretroviral therapy than rules-based genotype interpretation systems [Abstract 653]. 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006.
14. Larder BA, Wang D, Revell A. Application of artificial neural networks for decision support in medicine. In: Li-vingstone DS, ed. Artificial Neural Networks: Methods and Applications. New York: Humana Press (Springer-Verlag), New York, 2008, 119-132.
15. Beerenwinkel N, Daumer M, Oette M, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 geno-types. Nucleic Acids Res 2003;31:3850-3855.
16. Beerenwinkel N, Sing T, Lengauer T, et al. Computational models for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005;21:3943-3950.
17. DiRienzo G, DeGruttola V. Collaborative HIV resistance-response database: Sample size for detection of relationships between HIV-1 genotype and HIV-1 RNA response using a non-parametric approach. Antivir Ther 2002;7:S71.
18. Larder BA, DeGruttola V, Hammer S, et al. The international HIV resistance response database initiative: A new global collaborative approach to relating viral genotype treatment to clinical outcome. Antivir Ther 2002;7:S84.
19. Larder BA, Wang D, Revell A, et al. The development of artificial neural networks to predict virological response to combination HIV therapy. Antivir Ther 2007;12:15-24.
20. Larder BA, Wang D, Revell AD, et al. The development of computational models that accurately predict virological response to HIV therapy to power an online treatment se-lection tool. Antivir Ther 2010;15:A89.
21. Revell AD, Wang D, Harrigan R, et al. Modelling response to HIV therapy without a genotype\An argument for viral load monitoring in resource-limited settings. J Antimicrob Chemother 2010;65:605-607.